BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Pharmaxis Ltd 

Unit 2, 10 Rodborough Road

Frenchs Forest  New South Wales  2086  Australia
Phone: 61-2-9451-5961 Fax: 61-2-9451-3622


View Clinical Trials from BioPharm Insight

Pharmaxis is a specialist pharmaceutical company committed to the research, development and commercialisation of human therapeutic products that improve the clinical management of chronic respiratory and autoimmune diseases.

Pharmaxis has a diversified portfolio of products at various stages of development which target attractive international markets across a range of diseases.

AridolTM: addresses a new market - providing a clinical management tool for asthma and COPD. It is scheduled to complete Phase III clinical trials in Q3 of 2004, with the initial product launch scheduled for Q3 of 2005.

BronchitolTM: a new therapeutic targeting cystic fibrosis, bronchiectasis, and chronic bronchitis. It is scheduled to complete Phase II clinical trials in H2 of 2004, with Phase III clinical trials scheduled to commence in H1 of 2005. The initial product launch is scheduled for CY 2008

PXS25: inhibits immune cell trafficking and is being developed for the treatment of multiple sclerosis and other autoimmune diseases.

PXS2000: represents a new class of anti-inflammatory agent under development for rheumatoid arthritis.

Pharmaxis is building a fully integrated specialist pharmaceutical company with activities spanning research and development through to manufacture, marketing, and distribution.

The company's board of directors and senior management team has extensive experience in developing and commercializing successful breakthrough products.

Last Updated: 05-20-04

 Key Statistics

Ownership: Public

Web Site: Pharmaxis Ltd
Symbol: PXS.AX


 Company News
Pharmaxis Ltd (PXS.AX) Slashes 30 Pct. of Jobs 5/28/2013 7:32:43 AM
Pharmaxis Ltd (PXS.AX) Chief Steps Down in Shake-Up 3/12/2013 7:47:25 AM
Pharmaxis Ltd (PXS.AX) Reels After Verdict on Key Drug, Bounces Back With $40 Million in Pocket 1/31/2013 8:08:20 AM
Pharmaxis Ltd (PXS.AX) Receives Approval to Market Bronchitol in the EU 4/27/2012 8:23:34 AM
Pharmaxis Ltd (PXS.AX) Announces ARIDOL(R) (Mannitol Inhalation Powder) Bronchial Challenge Test Kit J-code 1/4/2012 9:35:03 AM
Pharmaxis Ltd (PXS.AX) Receives J-Code For ARIDOL(R) (Mannitol Inhalation Powder) Bronchial Challenge Test Kit 11/7/2011 2:11:14 PM
Pharmaxis Ltd (PXS.AX) Announces Major Milestone: Positive Bronchitol Opinion for Europe 10/25/2011 9:54:22 AM
Pharmaxis Ltd (PXS.AX) Announces Major Milestone: Positive Bronchitol Opinion for Europe 10/24/2011 1:38:00 PM
Pharmaxis Ltd (PXS.AX) Receives Negative Bronchitol Trend Vote from CHMP; Shares Dived 70 Pct at Market Close 5/26/2011 8:38:29 AM
First Time Unlucky for Australian Listing of Pharmaxis Ltd (PXS.AX)'s Cystic Fibrosis Drug 4/27/2011 7:52:20 AM